echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Guangdong Chinese patent medicines are collected in quantities, and exclusive varieties are bid farewell to the golden years

    Guangdong Chinese patent medicines are collected in quantities, and exclusive varieties are bid farewell to the golden years

    • Last Update: 2021-09-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On September 14, the Guangdong Provincial Drug Exchange Center issued a notice on soliciting opinions on the "Guangdong Union Qingkailing and other 58 drug groups' procurement documents (consultation draft)", which included a large amount and high purchase amount in the basic medical insurance drug catalog Guangdong takes the lead in all the dosage forms and specifications of 58 generic medicines in China.
    The participating provinces (regions) include Shanxi, Henan, Hainan, Ningxia, Qinghai, and Xinjiang
    .
    The target 6 provinces are spread across the southeast, northwest, and northwestern regions of the country, but the volume is not as large as previously expected
    .
     
    At this point, Guangdong’s 281 group purchasing varieties were divided into three, and 45 national procurement renewals took the lead in soliciting opinions, and then 58 Chinese patent medicines came in volume purchasing.
    The real big move should be the next 178 chemical medicine varieties.
    Collectively
    .
    Three batches in one round, synchronization starts, synchronization ends, and the execution is completed within the year
    .
    And the exclusive varieties, starting from today, will bid farewell to the golden years
    .
     
    Purchase order details
     
      In the same generic name, it is normal to merge the various dosage forms of medicines, and this rule is also adopted in Shanxi and other provinces
    .
    The most important thing is that drugs with the same prescription but different drug names are combined in principle, and drugs with the same or similar drug names but different prescriptions are divided into different groups according to their formulas or ingredients
    .
     
      A Chinese medicine prescription is a written document containing the name, quantity, decoction method, etc.
    of the Chinese medicine and preparation of any Chinese medicine preparation.
    It is a written record and voucher for the physician's syndrome differentiation and treatment, reflecting the physician's syndrome differentiation legislation and medication requirements
    .
    This time Guangdong directly merged the same types of prescriptions as a must
    .
    It is intriguing that medicines with the same or similar names but different prescriptions are distinguished by prescriptions or ingredients
    .
    This is equivalent to digging more carefully, not only looking at the prescription, but also looking at the prescription
    .
     
      In Guangdong’s grouping, layer by layer, layer by layer, layer by layer, the thinner the layer, the greater the chance of a big merger
    .
     
      Exclusive variety "Team Fight"
     
      Exclusive products that cannot be merged in accordance with the above principles, according to the key drug monitoring catalog (hereinafter referred to as "Monitoring Exclusive Products") announced by the Guangdong Provincial Health and Health Department and the average daily treatment cost (refers to the company ’s daily average treatment cost, daily average treatment cost) = The price of the smallest unit of measurement × the average daily treatment volume corresponding to the product specification) The price range is divided into 4 groups: 1.
    Monitor exclusive products; 2.
    Products with average daily treatment costs ≤ RMB 5; 3.
    Average daily treatment costs Products with 5 to 15 yuan (inclusive); 4.
    Products with an average daily treatment cost> 15 yuan
    .
     
      This is equivalent to dividing four files, similar to the all-round monitoring of the monitored varieties, the varieties similar to low-cost drugs are listed in a separate track, and the popular varieties with an average daily cost of 5 to 15 yuan are given priority care.
    The average daily cost Varieties higher than 15 yuan may usher in price cuts
    .
     
      Divide AB bills according to the number of days taken
     
      On the basis of the above, two types of purchase orders, A and B , are divided
    .
    Exclusively, only purchase order A is divided into the above 4 groups, and order B is not set
    .
     
      The focus of the high-energy early warning ahead is: other products are based on the first-year pre-purchased quantity of each specification of the same generic drug of the same company and the average daily treatment volume of the corresponding specification, converted into the total number of days taken by the same company in the same group, and calculated the same The proportion of the total number of days taken by each company in the group to the total number of days taken by all companies in the alliance area is used as the basis for division.
    The products of enterprises with a cumulative proportion of 80% from high to low are listed in the A purchase order, and the rest are listed in the B purchase order; If the number of A purchase order companies is less than 3, the 3 companies will be added to the A purchase order according to the proportion from high to low
    .
     
      That is to say, Guangdong divides the AB purchase orders based on the proportion of the total number of days taken by the same group and the same company in the same group of Chinese patent drugs
    .
    In the past, it was often heard that the AB orders were divided according to the purchase volume.
    This time, Guangdong broke the precedent and divided them according to the number of days taken
    .
     
      Double price limit
     
      First, the company’s quotation is calculated based on the average daily treatment cost
    .
    This trick appeared in the "Ten Standards" in Fujian that year
    .
     
      The second is that those who are unwilling to participate and lose bids still have the opportunity to file for the record
    .
     
      The third is the difference ratio, the representative product
    .
    Indispensable
    .
     
      The fourth is cascade quotation
    .
    The cascade quotation requires double price limit, the highest average daily treatment cost and the average daily treatment cost calculated by the company's national lowest price
    .
    There are several key points here: 1.
    Two cascade quotations must participate at the same time
    .
    2.
    To be within the range of relevant dosage forms
    .
    3.
    The two cascade quotations must be in sequence, that is, if P2≥P1, the two cascade quotations of the company shall be regarded as invalid quotations
    .
    4.
    Those who participate in the second rung must be within the scope of the first rung
    .
     
      At the same time, take the amount on demand
    .
    Start with 50% of monitoring exclusive products, and 70% of non-monitoring exclusive products and non-exclusive products
    .
    It is worth noting that the purchase order only quotes one price; if multiple prices are quoted, it will be deemed as an invalid quotation
    .
     
      Proposed selection to see the overall decline
     
      The key points are as follows:
     
      1.
    Take the lower of the two to get the qualification for the first step of the A single
    .
    Note that there is no distinction between exclusive and non-exclusive
    .
     
      2.
    The second-tier bidding of the non-exclusive product A purchase order is planned to be selected based on the overall decrease of 50%, and the competition is fierce
    .
     
      3.
    The second-tier bidding of the exclusive product A purchase order depends on the order of P2 and P1 decline.
    The top 50% of the monitoring exclusive have a chance, and the top 70% of the non-monitoring exclusive have a chance
    .
    If there are multiple companies with the same final drop, they will be eliminated together
    .
    The author recommends that bidding companies should not play a one-point or two-point drop.
    If they want to be selected, they must widen the gap
    .
     
      4.
    B purchase order plans to choose companies to look at the low value, and even more at 50% (sorted by the "comparable unit price" from low to high, ranking in the top 50%)
    .
     
      The brief summary of Guangdong’s centralized procurement plan for Chinese patent medicines is to try to combine the same prescriptions and prescriptions together, try to combine the exclusive ones, try to balance prices from the perspective of average daily costs, and maintain the status quo of the market structure.
    While not changing, enterprises are encouraged to drop more and take more
    .
     
      After all, in the same group, so many varieties that were originally "old and dead", now finally have the opportunity to meet each other
    .
    The usual inter-enterprise academic conferences, online conferences, satellite conferences, and department conferences are so lively, and now we are starting to fight for prices
    .
    After all, the price is not a trivial matter.
    Without the price, everything will return to its original point
    .
    And for many years, proprietary Chinese medicine companies that have developed well based on exclusive varieties, exclusive formulations, and exclusive specifications, from now on, please give up your old thinking and prepare for battle
    .
      On September 14, the Guangdong Provincial Drug Exchange Center issued a notice on soliciting opinions on the "Guangdong Union Qingkailing and other 58 drug groups' procurement documents (consultation draft)", which included a large amount and high purchase amount in the basic medical insurance drug catalog Guangdong takes the lead in all the dosage forms and specifications of 58 generic medicines in China.
    The participating provinces (regions) include Shanxi, Henan, Hainan, Ningxia, Qinghai, and Xinjiang
    .
    The target 6 provinces are spread across the southeast, northwest, and northwestern regions of the country, but the volume is not as large as previously expected
    .
     
      At this point, Guangdong’s 281 group purchasing varieties were divided into three, and 45 national procurement renewals took the lead in soliciting opinions, and then 58 Chinese patent medicines came in volume purchasing.
    The real big move should be the next 178 chemical medicine varieties.
    Collectively
    .
    Three batches in one round, synchronization starts, synchronization ends, and the execution is completed within the year
    .
    And the exclusive varieties, starting from today, will bid farewell to the golden years
    .
     
      Purchase order details
     
      In the same generic name, it is normal to merge the various dosage forms of medicines, and this rule is also adopted in Shanxi and other provinces
    .
    The most important thing is that drugs with the same prescription but different drug names are combined in principle, and drugs with the same or similar drug names but different prescriptions are divided into different groups according to their formulas or ingredients
    .
     
      A Chinese medicine prescription is a written document containing the name, quantity, decoction method, etc.
    of the Chinese medicine and preparation of any Chinese medicine preparation.
    It is a written record and voucher for the physician's syndrome differentiation and treatment, reflecting the physician's syndrome differentiation legislation and medication requirements
    .
    This time Guangdong directly merged the same types of prescriptions as a must
    .
    It is intriguing that medicines with the same or similar names but different prescriptions are distinguished by prescriptions or ingredients
    .
    This is equivalent to digging more carefully, not only looking at the prescription, but also looking at the prescription
    .
     
      In Guangdong’s grouping, layer by layer, layer by layer, layer by layer, the thinner the layer, the greater the chance of a big merger
    .
     
      Exclusive variety "Team Fight"
     
      Exclusive products that cannot be merged in accordance with the above principles, according to the key drug monitoring catalog (hereinafter referred to as "Monitoring Exclusive Products") announced by the Guangdong Provincial Health and Health Department and the average daily treatment cost (refers to the company ’s daily average treatment cost, daily average treatment cost) = The price of the smallest unit of measurement × the average daily treatment volume corresponding to the product specification) The price range is divided into 4 groups: 1.
    Monitor exclusive products; 2.
    Products with average daily treatment costs ≤ RMB 5; 3.
    Average daily treatment costs Products with 5 to 15 yuan (inclusive); 4.
    Products with an average daily treatment cost> 15 yuan
    .
     
      This is equivalent to dividing four files, similar to the all-round monitoring of the monitored varieties, the varieties similar to low-cost drugs are listed in a separate track, and the popular varieties with an average daily cost of 5 to 15 yuan are given priority care.
    The average daily cost Varieties higher than 15 yuan may usher in price cuts
    .
     
      Divide AB bills according to the number of days taken
     
      On the basis of the above, two types of purchase orders, A and B , are divided
    .
    Exclusively, only purchase order A is divided into the above 4 groups, and order B is not set
    .
     
      The focus of the high-energy early warning ahead is: other products are based on the first-year pre-purchased quantity of each specification of the same generic drug of the same company and the average daily treatment volume of the corresponding specification, converted into the total number of days taken by the same company in the same group, and calculated the same The proportion of the total number of days taken by each company in the group to the total number of days taken by all companies in the alliance area is used as the basis for division.
    The products of enterprises with a cumulative proportion of 80% from high to low are listed in the A purchase order, and the rest are listed in the B purchase order; If the number of A purchase order companies is less than 3, the 3 companies will be added to the A purchase order according to the proportion from high to low
    .
     
      That is to say, Guangdong divides the AB purchase orders based on the proportion of the total number of days taken by the same group and the same company in the same group of Chinese patent drugs
    .
    In the past, it was often heard that the AB orders were divided according to the purchase volume.
    This time, Guangdong broke the precedent and divided them according to the number of days taken
    .
     
      Double price limit
     
      First, the company’s quotation is calculated based on the average daily treatment cost
    .
    This trick appeared in the "Ten Standards" in Fujian that year
    .
     
      The second is that those who are unwilling to participate and lose bids still have the opportunity to file for the record
    .
     
      The third is the difference ratio, the representative product
    .
    Indispensable
    .
     
      The fourth is cascade quotation
    .
    The cascade quotation requires double price limit, the highest average daily treatment cost and the average daily treatment cost calculated by the company's national lowest price
    .
    There are several key points here: 1.
    Two cascade quotations must participate at the same time
    .
    2.
    To be within the range of relevant dosage forms
    .
    3.
    The two cascade quotations must be in sequence, that is, if P2≥P1, the two cascade quotations of the company shall be regarded as invalid quotations
    .
    4.
    Those who participate in the second rung must be within the scope of the first rung
    .
     
      At the same time, take the amount on demand
    .
    Start with 50% of monitoring exclusive products, and 70% of non-monitoring exclusive products and non-exclusive products
    .
    It is worth noting that the purchase order only quotes one price; if multiple prices are quoted, it will be deemed as an invalid quotation
    .
     
      Proposed selection to see the overall decline
     
      The key points are as follows:
     
      1.
    Take the lower of the two to get the qualification for the first step of the A single
    .
    Note that there is no distinction between exclusive and non-exclusive
    .
     
      2.
    The second-tier bidding of the non-exclusive product A purchase order is planned to be selected based on the overall decrease of 50%, and the competition is fierce
    .
     
      3.
    The second-tier bidding of the exclusive product A purchase order depends on the order of P2 and P1 decline.
    The top 50% of the monitoring exclusive have a chance, and the top 70% of the non-monitoring exclusive have a chance
    .
    If there are multiple companies with the same final drop, they will be eliminated together
    .
    The author recommends that bidding companies should not play a one-point or two-point drop.
    If they want to be selected, they must widen the gap
    .
     
      4.
    B purchase order plans to choose companies to look at the low value, and even more at 50% (sorted by the "comparable unit price" from low to high, ranking in the top 50%)
    .
     
      The brief summary of Guangdong’s centralized procurement plan for Chinese patent medicines is to try to combine the same prescriptions and prescriptions together, try to combine the exclusive ones, try to balance prices from the perspective of average daily costs, and maintain the status quo of the market structure.
    While not changing, enterprises are encouraged to drop more and take more
    .
     
      After all, in the same group, so many varieties that were originally "old and dead", now finally have the opportunity to meet each other
    .
    The usual inter-enterprise academic conferences, online conferences, satellite conferences, and department conferences are so lively, and now we are starting to fight for prices
    .
    After all, the price is not a trivial matter.
    Without the price, everything will return to its original point
    .
    And for many years, proprietary Chinese medicine companies that have developed well based on exclusive varieties, exclusive formulations, and exclusive specifications, from now on, please give up your old thinking and prepare for battle
    .
      On September 14, the Guangdong Provincial Drug Exchange Center issued a notice on soliciting opinions on the "Guangdong Union Qingkailing and other 58 drug groups' procurement documents (consultation draft)", which included a large amount and high purchase amount in the basic medical insurance drug catalog Guangdong takes the lead in all the dosage forms and specifications of 58 generic medicines in China.
    The participating provinces (regions) include Shanxi, Henan, Hainan, Ningxia, Qinghai, and Xinjiang
    .
    The target 6 provinces are spread across the southeast, northwest, and northwestern regions of the country, but the volume is not as large as previously expected
    .
     
      At this point, Guangdong’s 281 group purchasing varieties were divided into three, and 45 national procurement renewals took the lead in soliciting opinions, and then 58 Chinese patent medicines came in volume purchasing.
    The real big move should be the next 178 chemical medicine varieties.
    Collectively
    .
    Three batches in one round, synchronization starts, synchronization ends, and the execution is completed within the year
    .
    And the exclusive varieties, starting from today, will bid farewell to the golden years
    .
    Medicine, medicine, medicine
     
      Purchase order details
      Purchase order details
     
      In the same generic name, it is normal to merge the various dosage forms of medicines, and this rule is also adopted in Shanxi and other provinces
    .
    The most important thing is that drugs with the same prescription but different drug names are combined in principle, and drugs with the same or similar drug names but different prescriptions are divided into different groups according to their formulas or ingredients
    .
     
      A Chinese medicine prescription is a written document containing the name, quantity, decoction method, etc.
    of the Chinese medicine and preparation of any Chinese medicine preparation.
    It is a written record and voucher for the physician's syndrome differentiation and treatment, reflecting the physician's syndrome differentiation legislation and medication requirements
    .
    This time Guangdong directly merged the same types of prescriptions as a must
    .
    It is intriguing that medicines with the same or similar names but different prescriptions are distinguished by prescriptions or ingredients
    .
    This is equivalent to digging more carefully, not only looking at the prescription, but also looking at the prescription
    .
     
      In Guangdong’s grouping, layer by layer, layer by layer, layer by layer, the thinner the layer, the greater the chance of a big merger
    .
     
      Exclusive variety "Team Fight"
      Exclusive variety "Team Fight"
     
      Exclusive products that cannot be merged in accordance with the above principles, according to the key drug monitoring catalog (hereinafter referred to as "Monitoring Exclusive Products") announced by the Guangdong Provincial Health and Health Department and the average daily treatment cost (refers to the company ’s daily average treatment cost, daily average treatment cost) = The price of the smallest unit of measurement × the average daily treatment volume corresponding to the product specification) The price range is divided into 4 groups: 1.
    Monitor exclusive products; 2.
    Products with average daily treatment costs ≤ RMB 5; 3.
    Average daily treatment costs Products with 5 to 15 yuan (inclusive); 4.
    Products with an average daily treatment cost> 15 yuan
    .
    Enterprise business enterprise
     
      This is equivalent to dividing four files, similar to the all-round monitoring of the monitored varieties, the varieties similar to low-cost drugs are listed in a separate track, and the popular varieties with an average daily cost of 5 to 15 yuan are given priority care.
    The average daily cost Varieties higher than 15 yuan may usher in price cuts
    .
     
      Divide AB bills according to the number of days taken
      Divide AB bills according to the number of days taken
     
      On the basis of the above, two types of purchase orders, A and B , are divided
    .
    Exclusively, only purchase order A is divided into the above 4 groups, and order B is not set
    .
    Procurement Procurement Procurement
     
      The focus of the high-energy early warning ahead is: other products are based on the first-year pre-purchased quantity of each specification of the same generic drug of the same company and the average daily treatment volume of the corresponding specification, converted into the total number of days taken by the same company in the same group, and calculated the same The proportion of the total number of days taken by each company in the group to the total number of days taken by all companies in the alliance area is used as the basis for division.
    The products of enterprises with a cumulative proportion of 80% from high to low are listed in the A purchase order, and the rest are listed in the B purchase order; If the number of A purchase order companies is less than 3, the 3 companies will be added to the A purchase order according to the proportion from high to low
    .
     
      That is to say, Guangdong divides the AB purchase orders based on the proportion of the total number of days taken by the same group and the same company in the same group of Chinese patent drugs
    .
    In the past, it was often heard that the AB orders were divided according to the purchase volume.
    This time, Guangdong broke the precedent and divided them according to the number of days taken
    .
     
      Double price limit
      Double price limit
     
      First, the company’s quotation is calculated based on the average daily treatment cost
    .
    This trick appeared in the "Ten Standards" in Fujian that year
    .
     
      The second is that those who are unwilling to participate and lose bids still have the opportunity to file for the record
    .
     
      The third is the difference ratio, the representative product
    .
    Indispensable
    .
     
      The fourth is cascade quotation
    .
    The cascade quotation requires double price limit, the highest average daily treatment cost and the average daily treatment cost calculated by the company's national lowest price
    .
    There are several key points here: 1.
    Two cascade quotations must participate at the same time
    .
    2.
    To be within the range of relevant dosage forms
    .
    3.
    The two cascade quotations must be in sequence, that is, if P2≥P1, the two cascade quotations of the company shall be regarded as invalid quotations
    .
    4.
    Those who participate in the second rung must be within the scope of the first rung
    .
     
      At the same time, take the amount on demand
    .
    Start with 50% of monitoring exclusive products, and 70% of non-monitoring exclusive products and non-exclusive products
    .
    It is worth noting that the purchase order only quotes one price; if multiple prices are quoted, it will be deemed as an invalid quotation
    .
     
      Proposed selection to see the overall decline
      Proposed selection to see the overall decline
     
      The key points are as follows:
      The key points are as follows:
     
      1.
    Take the lower of the two to get the qualification for the first step of the A single
    .
    Note that there is no distinction between exclusive and non-exclusive
    .
     
      2.
    The second-tier bidding of the non-exclusive product A purchase order is planned to be selected based on the overall decrease of 50%, and the competition is fierce
    .
     
      3.
    The second-tier bidding of the exclusive product A purchase order depends on the order of P2 and P1 decline.
    The top 50% of the monitoring exclusive have a chance, and the top 70% of the non-monitoring exclusive have a chance
    .
    If there are multiple companies with the same final drop, they will be eliminated together
    .
    The author recommends that bidding companies should not play a one-point or two-point drop.
    If they want to be selected, they must widen the gap
    .
     
      4.
    B purchase order plans to choose companies to look at the low value, and even more at 50% (sorted by the "comparable unit price" from low to high, ranking in the top 50%)
    .
     
      The brief summary of Guangdong’s centralized procurement plan for Chinese patent medicines is to try to combine the same prescriptions and prescriptions together, try to combine the exclusive ones, try to balance prices from the perspective of average daily costs, and maintain the status quo of the market structure.
    While not changing, enterprises are encouraged to drop more and take more
    .
     
      After all, in the same group, so many varieties that were originally "old and dead", now finally have the opportunity to meet each other
    .
    The usual inter-enterprise academic conferences, online conferences, satellite conferences, and department conferences are so lively, and now we are starting to fight for prices
    .
    After all, the price is not a trivial matter.
    Without the price, everything will return to its original point
    .
    And for many years, proprietary Chinese medicine companies that have developed well based on exclusive varieties, exclusive formulations, and exclusive specifications, from now on, please give up your old thinking and prepare for battle
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.